The FINEGUST study, sponsored by Bayer, aims to evaluate the utilization of finerenone and other treatments for chronic kidney disease (CKD) and type 2 diabetes (T2D) in real-world settings across five countries. With finerenone being a non-steroidal mineralocorticoid receptor antagonist (nsMRA), its market potential is significant, particularly as it addresses a critical unmet need in managing CKD in T2D patients. The study's findings could influence treatment guidelines and prescribing patterns, potentially enhancing finerenone's market share against competitors such as SGLT2 inhibitors and GLP-1 receptor agonists. The completion of this observational study by September 2024 will provide valuable insights into treatment patterns and patient outcomes, which may inform Bayer's strategic positioning and marketing efforts in the CKD and T2D therapeutic landscape.